Skyfii Ltd (ASX: SKF) is the company engaged in the business of helping physical venues measure, predict, and influence customer behaviour. Today it has announced, the signing of a two-year contract, with Quick Service Restaurants (QSR) operated Nandoâs.
The company highlighted that it would deploy Skyfiiâs Software-as-a-Service (SaaS) recurring revenue âIO Platformâ, in more than 260 Nandoâs restaurants across South Africa.
It is to be noted that, SKF last year had won Nandoâs Australian, and Euro contract. At present, across 520 Nandoâs restaurants, Skyfiiâs IO Platform has been deployed. With todayâs announcement, the total number of Nandoâs restaurants globally running the SaaS recurring revenue IO platform stands at 780.
The company, in its press release, informed that this contract would get deployed in partnership with Infoprotect, a Skyfii authorised South African reseller. This reseller is a major ICT solution provider, offering managed solutions across five pillars.
The Chief Executive Officer of Infoprotect, Brad Fraser believes that this partnership with Skyfii would allow Nandoâs to grow its customer base, engage directly and collect valuable customer data, thanks to its single easy to use platform.
The press release highlighted, the value delivered by Skyfii to Nandoâs. The IO Connect solution would provide Nandoâs South Africa a seamless guest WiFi captive portal experience, enriching the customer database, and deliver personalised content. Nandoâs would be able to optimise customer engagement and enhance in-venue performance.
Wayne Arthur, the Chief Executive Officer of Skyfii, highlighted the traction SKF is witnessing post-Nandoâs Australia, and other Nandoâs international chain contracts. He believes that post 780 restaurants globally, Skyfiis solutions is a valued component of the Quick Service Restaurant industry.
Todayâs announcement comes, on the back of Skyfiiâs 5 March 2019, announcement of a three-year Master Services Agreement, with the North American retail chain group Cafaro. More on this could be read here.
Also, SKF on 26th February 2019, announced its first museum client within the United States of America. The company had signed a twelve-month contract, with the San Francisco Museum of Modern Art. The San Francisco Museum hosts more than one million visitors annually. This deal was a part of SKFâs cultural centre vertical. This vertical had announced, a partnership with the National Museum of Australia, in July 2017.
SKFâs Q2 FY19 results details could be read here.
The company posted a good set of 1H FY 2019 results. The group generated operating revenue of $4,666,345 in 1HFY19 vs. $2,677,161 in 1HFY18 a jump of 74.3 on previous corresponding period (pcp). The revenue growth was backed by a 51.7% increase in recurring revenues on pcp basis. The group reported an EBITDA turn-around by posting EBITDA of $291,979 vs. an EBITDA loss of $303,454 in 1HFY18. However, the company reported a net loss after tax of $1,233,754 for 1HFY19. The company did not declare any dividend for the period.
The stock has been in an uptrend in the recent past. It has moved up by 6.45%, and 10.00%, in the past three months, and one month respectively.
By the closure of the trading session, the shares of SKF stood at A$0.165 on ASX (As on 07 March 2019).
Skyfiiâs Ltd (ASX: SKF) market capitalization stands at circa A$51.51 million. The Stock has noted the 52-week high price of A$0.230 and 52-week low price of A$0.125. As per the latest ASX declaration the, company EPS stood at -0.007 AUD.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.